Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
Abbott Medical Device Company Intelligence Report
Management Report
Published: October 2009
Pages: 50
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 295.00 Buy Now!
Research from: Espicom
Sector: Medical Devices
Medical Device Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available.
Founded in 1888 by Dr Wallace Abbott, a Chicago physician, Abbott is a healthcare company that develops and manufactures products and services that span the continuum of care – from prevention and diagnosis to treatment and cure. Abbott's principal businesses are pharmaceutical, nutritional and medical products, including diagnostics, cardiovascular devices and vision care.
The company’s reportable segments are as follows:
Vascular - consisting of coronary, endovascular, vessel closure and other vascular products.
Diagnostic - including diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites.
Pharmaceutical - comprising a range of adult and paediatric pharmaceutical products.
Nutritional - consisting of adult and paediatric nutritional products.
The company also has an ‘Other’ segment, which includes diabetes, bulk pharmaceuticals and animal health products, as well as the operations of the recently-acquired Advanced Medical Optics (now known as Abbot Medical Optics, or AMO), a producer of ophthalmic surgical and eye care products.
The February 2009 acquisition of AMO marked Abbott’s entry into the vision care industry with a market-leading company that generates in excess of US$1 billion in annual sales. In September 2009, Abbott cemented its expansion into the ophthalmic market with a definitive agreement to acquire Visiogen for US$400 million in cash, providing the company with a next-generation accommodating intra-ocular lens (IOL) technology to address presbyopia for cataract patients.
In October 2008, Abbott sold its Abbott Spine division, which developed and manufactured devices to treat spine disease, in order to focus on its core businesses and with the intention of entering new sectors, such as ophthalmology.
Headquartered in north suburban Chicago, Abbott serves customers in more than 130 countries through an employee base of more than 72,000 at more than 100 manufacturing, distribution, research and development, and other locations around the world.
The principal market for Abbott’s common shares is the New York Stock Exchange. Shares are also listed on the Chicago Stock Exchange and traded on various regional and electronic exchanges. Outside the US, Abbott’s shares are listed on the London Stock Exchange and the Swiss Stock Exchange.
The company’s reportable segments are as follows:
Vascular - consisting of coronary, endovascular, vessel closure and other vascular products.
Diagnostic - including diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites.
Pharmaceutical - comprising a range of adult and paediatric pharmaceutical products.
Nutritional - consisting of adult and paediatric nutritional products.
The company also has an ‘Other’ segment, which includes diabetes, bulk pharmaceuticals and animal health products, as well as the operations of the recently-acquired Advanced Medical Optics (now known as Abbot Medical Optics, or AMO), a producer of ophthalmic surgical and eye care products.
The February 2009 acquisition of AMO marked Abbott’s entry into the vision care industry with a market-leading company that generates in excess of US$1 billion in annual sales. In September 2009, Abbott cemented its expansion into the ophthalmic market with a definitive agreement to acquire Visiogen for US$400 million in cash, providing the company with a next-generation accommodating intra-ocular lens (IOL) technology to address presbyopia for cataract patients.
In October 2008, Abbott sold its Abbott Spine division, which developed and manufactured devices to treat spine disease, in order to focus on its core businesses and with the intention of entering new sectors, such as ophthalmology.
Headquartered in north suburban Chicago, Abbott serves customers in more than 130 countries through an employee base of more than 72,000 at more than 100 manufacturing, distribution, research and development, and other locations around the world.
The principal market for Abbott’s common shares is the New York Stock Exchange. Shares are also listed on the Chicago Stock Exchange and traded on various regional and electronic exchanges. Outside the US, Abbott’s shares are listed on the London Stock Exchange and the Swiss Stock Exchange.